Handbook of Disease Burdens and Quality of Life Measures pp 2781-2794 | Cite as
Chemotherapy for Brain Metastasis and Quality of Life
Brain metastases incidence is increasing among patients with solid tumors. Treatment options are limited and frequently the palliative approaches remain the standard treatment to relieve neurologic symptoms with a decrease in survival and quality of life. Therapeutic approaches to brain metastases include surgery, whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), and chemotherapy.
For patients with multiple brain metastases, improvement in quality of life and neuralgic function remain important objectives. In this chapter the current role of chemotherapy and the impact on the Quality of life in these patients is summarized.
Temozolomide, an oral imidazotetrazinone methylating agent, is highly bio-available after oral administration, has excellent central nervous system penetration, and reaches the brain in therapeutic concentrations. Tolerability of this agent has been confirmed by clinical trials in patients with BM.
Several combination chemotherapy in first-line treatment for brain metastases was investigated, and in newly diagnosed brain metastases, the tumors are responsive as the primary systemic cancer, as demonstrated by several phase II studies.
The results of recent trials support the efficacy and safety of WBRT and chemotherapy in the treatment of patients with BM from a variety of solid tumors. The data show that this choice can also offer significant palliation for BM, improving global Quality of Life.
KeywordsBrain Metastasis Human Epidermal Growth Factor Receptor Neurocognitive Function Multiple Brain Metastasis Diagnose Brain Metastasis
List of Abbreviations:
central nervous system
epidermal growth factor receptor
functional assessment of cancer therapy
Karnofsky performance status
magnetic resonance imaging
non small cell lung cancer
quality of life
recursive partitioning analysis
radiation therapy oncology group
whole brain radiotherapy
- Dardoufas C, Miliadou A, Skarleas C, Kouloulias V, Mavroidi P, Couvaris J, Gennatas K, Vassilaki M, Gogas H, Polyzos A, Couvoussis E, Vlachos L. (2001). Proc Am Soc Clin Oncol. 20: 75 (Abs 2048).Google Scholar
- Friedman HS, Evans B, Reardon D, Quinn J, Rich J, Gururangan S, Stafford-Fox V, Chen C, Pati A, Schmidt W. (2003). Proc Am Soc Clin Oncol. 22: 102 (Abs. 408).Google Scholar
- Glantz M, Choy H, Chakravarthy A. (1999). Proc Am Soc Clin Oncol. 18: 140a, (Abstract 535).Google Scholar
- Lin NU, Carey LA, Liu MC, Younger J, Come SE, Bullitt E, Van Den Abbeele AD, Li X, Hochberg FH, Winer EP. (2006). J Clin Oncol. 24(Suppl 18): 503a.Google Scholar